Form 4: BioXcel Therapeutics Executive Sells Shares After Vesting of Restricted Stock Units
SEC Form 4 Filing
Vincent O'Neill, an executive at BioXcel Therapeutics, sold 5,556 shares of common stock after the vesting of 21,250 restricted stock units.
Summary
- On September 17, 2024, the Compensation Committee of BioXcel Therapeutics determined that performance conditions were met for 21,250 restricted stock units (PSUs) previously granted to Vincent O'Neill.
- These PSUs converted into shares of common stock on October 1, 2024.
- O'Neill then sold 5,556 shares on October 3, 2024, at a weighted average price of $0.55 per share.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
- Following the reported transaction, O'Neill beneficially owns 19,601 shares of BioXcel Therapeutics.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing related to an executive's stock transactions. It doesn't inherently convey positive or negative sentiment, but rather reports factual information.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies and are often related to compensation packages. The use of a 10b5-1 trading plan suggests the executive is selling shares in a pre-planned manner to avoid accusations of insider trading.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units (RSUs) or performance stock units (PSUs) that vest over time or upon achievement of certain milestones.
- The use of Rule 10b5-1 trading plans is a standard practice among corporate executives to manage their stock sales in compliance with insider trading regulations.
- Comparable companies in the biotechnology sector, such as Sage Therapeutics or Axsome Therapeutics, also utilize similar compensation and trading practices for their executives.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the relatively small number of shares sold and the use of a pre-arranged trading plan.
Key Dates
| Date | Description |
|---|---|
| December 14, 2023 | Reporting Person adopted a Rule 10b5-1 trading plan |
| September 17, 2024 | Compensation Committee determined performance conditions were met for 21,250 PSUs |
| October 1, 2024 | 21,250 shares of common stock became issuable to the Reporting Person |
| October 3, 2024 | Reporting Person sold 5,556 shares of common stock |
Keywords
BioXcel Therapeutics, BTAI, Form 4, Insider Trading, Vincent O'Neill, Restricted Stock Units, Rule 10b5-1, Executive Compensation, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.